Medicine's Forgotten Drainage System
WhiteSwell's experimental heart failure device works by pumping lymph, a move that challenges decades of treatment focused on squeezing the heart harder and forcing the kidneys to produce more urine. Results from the 40-patient DELTA-HF trial, presented May 9-12 at the Heart Failure 2026 Congress in Barcelona and published simultaneously in the European Journal of Heart Failure, show 82.5% of patients stayed out of the hospital for six months after a single treatment session. One patient died during the vascular access procedure before the device was deployed, exposing both the promise and the peril of targeting a system medicine has largely ignored.
The eLym System addresses what researchers now recognize as a plumbing failure, not just a pump failure. In acute decompensated heart failure, fluid accumulates in the interstitial space, the microscopic gaps between cells where excess liquid pools when the body's drainage network can't keep pace. The lymphatic system, responsible for constantly draining this compartment, becomes overwhelmed. Standard treatment throws diuretics at the kidneys and tries to strengthen the heart's squeeze, but neither approach fixes the backed-up drainage. WhiteSwell's device goes straight to the thoracic duct, the body's main lymph channel, and manually creates the low-pressure zone needed to pull fluid out.
How the Device Works
The eLym system deploys through the left internal jugular vein into the innominate vein, where an endovenous micro-axial impeller pump sits near the thoracic duct. The pump runs for an average of 23 hours, creating negative pressure that pulls lymph from the overloaded interstitial space. In the DELTA-HF trial, this approach lowered thoracic duct pressure in 98% of cases. The device was successfully deployed in all 40 patients, who received treatment at multiple centers between late 2023 and early 2026.
These weren't typical heart failure patients. All had insufficient response to diuretics in the past, multiple comorbidities, elevated natriuretic peptides, and were taking at least 80 mg of furosemide daily, the population for whom standard care often fails. In diuretic non-responders like these, six-month event rates under standard care alone are expected to reach 50%, per the published study protocol [1]. The 82.5% who avoided heart failure hospitalization at six months represent a substantial improvement, though the small sample size and single-arm design mean the comparison isn't definitive.
The Numbers and the Death
At six months, DELTA-HF patients reached a median modified EVEREST clinical congestion score of zero, meaning no detectable fluid overload. They lost an average of 6.8 kg, and their kidney function remained stable, with median serum creatinine actually improving slightly from 1.26 mg/dL to 1.15 mg/dL. For a population where aggressive diuretic use typically degrades kidney function, that stability matters.
Two procedure-related serious adverse events occurred. One patient experienced severe low blood pressure that resolved after treatment. The other patient died from a vascular complication during the access procedure, before the device entered the body. The patient suffered a mediastinum hematoma, bleeding into the chest cavity between the lungs, during the attempt to thread the catheter through the jugular vein. The death highlights the fragility of the patient population: people with advanced heart failure, swollen tissues, and vasculature compromised by chronic illness and anticoagulation requirements.
WhiteSwell received FDA Breakthrough Device Designation for the eLym System, a pathway reserved for technologies addressing life-threatening conditions where no adequate treatment exists. The designation signals regulatory willingness to consider alternatives for patients who have, as the clinical trial language puts it, "run out of options." Whether that calculus holds when one in 40 patients dies during access, not from device malfunction but from the attempt to reach the target vessel, will be tested in the larger LYMPH-HF trial WhiteSwell plans to initiate later in 2026 across sites in the US, Europe, Canada, and Israel.
Why Lymphatics Were Overlooked
The lymphatic system has been medicine's afterthought in heart failure treatment, overshadowed by the heart-kidney axis that dominates textbooks and clinical guidelines. Researchers have spent decades refining drugs that make the heart contract more forcefully or block hormones that retain salt and water. The assumption was that if you fixed the pump or forced the kidneys to work harder, the fluid problem would resolve. But in acute decompensated heart failure, the interstitial space, where the lymphatic system operates, is the major compartment where excess fluid actually accumulates, forming the peripheral congestion that sends patients to the emergency room.
The inefficiency of the lymphatic system in these patients isn't a secondary effect; it's central to why they decompensate. The thoracic duct, which drains lymph from most of the body back into the venous circulation near the heart, can't maintain the pressure gradient needed when venous pressures are chronically elevated. Fluid backs up, tissues swell, and no amount of diuretic will move liquid that's trapped outside the vascular space. WhiteSwell's approach, mechanically lowering thoracic duct pressure to restore drainage, treats the system that was failing all along.
What the Randomized Trial Must Answer
DELTA-HF was a feasibility study, designed to show the device could be deployed safely and produce a measurable effect. It succeeded on the second count and mostly succeeded on the first, with the critical exception of the access-related death. The upcoming LYMPH-HF trial will be randomized, comparing the eLym system against standard care in a head-to-head design that can definitively answer whether the drainage approach reduces hospitalizations and mortality compared to diuretics alone.
The trial will also clarify whether the vascular access risk can be managed with better patient selection or technique refinement. Threading catheters into the jugular and innominate veins of patients with tissue edema, anticoagulation, and friable vessels is inherently risky. The question isn't whether risk exists, it does, but whether the 82.5% who stayed out of the hospital justify the 2.5% procedural mortality rate in a population where doing nothing also carries a 50% chance of hospitalization or death within six months. That's the calculation regulators, clinicians, and patients will have to make as the device moves toward potential approval, and it's a calculation that only works if the randomized data holds up.